Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Tech Transfer Roundup: ProQR Partners With Foundation Fighting Blindness On Rare Vision-Loss Disorder

Fri, 03/23/2018 - 12:19pm

Galderma unveils seven-year partnership with Mount Sinai and Northwestern in atopic dermatitis. Beacon/Takeda and Zealand/UniQuest tie-ups both address gastrointestinal diseases.

      Related Stories 

GSK Secures EU & Japanese Approvals For Shingrix

Fri, 03/23/2018 - 9:30am

Hot on the heels of the FDA approval, GlaxoSmithKline has received the green light for its shingles vaccine Shingrix from...

      Related Stories 

Novartis' Siponimod Heads Towards Regulators As Experts Question Its Effects

Fri, 03/23/2018 - 9:29am

As Novartis prepares its imminent US filing for its Gilenya follow-up siponimod some experts are underwhelmed by its pivotal EXPAND...

      Related Stories 

Morphosys Seeks US Listing To Cement Corporate Developments

Fri, 03/23/2018 - 9:17am

German biotech Morphosys has filed an F-1 registration statement with the US Securities & Exchange Commission to list the ADSs...

      Related Stories 

CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC

Fri, 03/23/2018 - 9:03am

The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer...

      Related Stories 

Hyperkalemia Market Hots Up In EU with Okay for AZ's Lokelma

Fri, 03/23/2018 - 8:54am

Rival Vifor Pharma has predicted blockbuster status for Veltassa and AstraZeneca expects the same for its just-approved oral potassium-removing agent...

      Related Stories 

VIDEO: Zelluna Immunotherapy Seeks TCR Share Of Voice

Fri, 03/23/2018 - 4:16am

Immunotherapy is currently one of the hottest areas in biotech, so differentiating from the crowd is a major challenge for...

      Related Stories 

Finance Watch: The Curious Case Of Proteostasis' Short Attack

Thu, 03/22/2018 - 3:22pm

Proteostasis planned to raise cash this week, but scrapped the offering after an investor that shorted the stock published a...

      Related Stories 

Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

Thu, 03/22/2018 - 2:52pm

Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data...

      Related Stories 

VIDEO: Crescendo Aims To Increase IO Share Of Voice With Humabody Platform

Thu, 03/22/2018 - 3:32am

The Immuno-oncology space is a crowded and consequently represents a big challenge for small biotechs to get share of voice...

      Related Stories 

Drug Pricing: A Game Of Chutes & Ladders

Wed, 03/21/2018 - 1:58pm

The US drug pricing policy environment is facing changes. Much of the action, whether Congressional or regulatory, is good for...

      Related Stories 

Ilumya Becomes Sun's New Branded Specialty Drug Pillar

Wed, 03/21/2018 - 12:04pm

FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing...

      Related Stories 

Sun's Ilumya Poised To Be A Branded Specialty Pillar

Wed, 03/21/2018 - 12:04pm

FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market.

      Related Stories 

Turkey's Abdi Ibrahim Beats Multinationals On Domestic Pharma Market

Wed, 03/21/2018 - 10:59am

The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market...

      Related Stories